dixiegirl1035
I will do it, but I won't like it
- Joined
- Oct 5, 2017
- Messages
- 12,887
- Reaction score
- 99,731
AstraZenaca vaccine trial shows 90% efficacy when given as a half dose, followed by a full dose one month later. 62% efficacy in a separate trial with two full doses one month apart. Combined efficacy estimate is 70%. AstraZeneca - Research-Based BioPharmaceutical Company
COVID-19: Oxford vaccine is up to 90% effective in preventing coronavirus, tests show
I went back to reread, and I'm confused. @10ofRods, can you perhaps explain how this happens as I don't understand. In the article, it's reading like "less is more" for doing the first dose. Is it because the immune system is overwhelmed if given too high a dosage on the first round?
They said they would be releasing their full report within 24 hours, so I look forward to Drs Campbell, Seheult and Hansen (approved here at WS) covering such also.
Anyone else care to explain what is going on?
From your link:
"Professor Pollard went on: "We think that by giving smaller first dose we are setting up the immune response better to respond. We will dig in more to that. We have started work this morning."
He added: "It's critical to understand what everyone is measuring. What counts as COVID disease varies between different protocols.
"If you are only counting hospitalisations then we would have bigger efficacy. We count mild disease and that is much harder to protect against."
The results will be submitted to a scientific journal for peer review within 24 hours."
The above comments reinforce that they aren't doing the PCRs during testing to catch asymptomatics? I need to go back as that was something I noted when I reviewed the protocols. They only did PCR's when symptomatic.